Drug intelligence / Profile preview

compaccip

Development stage: Preclinical
Modality: Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
Administration: Intravitreal

Overview

Compaccip is referenced as an anti-VEGF agent used in combination with other therapies for ophthalmic indications, specifically in the context of clinical trials for visual function improvement. The available information suggests it is administered by injection and acts as a vascular endothelial growth factor (VEGF) inhibitor, a class of drugs commonly used to treat retinal diseases such as diabetic retinopathy and age-related macular degeneration by inhibiting abnormal blood vessel growth in the eye. However, no detailed molecular or pharmacological profile, developer, or regulatory status could be confirmed from available sources[8].

Brand names: compaccip
Other names: compaccip injection

Targets

VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on compaccip.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on compaccip.

Explore the full profile